content_image/280117.jpg content_image/280105.jpg content_image/280106.jpg content_image/280107.jpg
## inclusion in SRi indexes 

<img src='content_image/280117.jpg'>

Astellas is included in the following global “social responsible investment (SRI) indexes.” 

## wEBSiTES 

## CORPORATE WEBSITE 

<img src='content_image/280105.jpg'>

http://www.astellas.com/ en/ 

## Editorial policy 

With the aim of deepening stakeholders’ understanding of our business activities and CSR-based management, which is the basis for those activities, we have integrated our Annual Report with our CSR Report, and now publish an integrated Annual Report. 

The basis of this report is to provide an overview of the activities of Astellas Pharma Inc. and its consolidated subsidiaries worldwide in fiscal 2013, which covers the period from April 1, 2013 to March 31, 2014. In places where the period or scope differs from these parameters, we have provided clarification. This report also includes the latest information available at the time of publishing. The figures indicated in the fiscal 2013 status report for the field of “Environment,” however, present the results for fiscal 2013 (April 1, 2013 to March 31, 2014) in Japan and the calendar year 2013 (January 1, 2013 to December 31, 2013) for overseas operations. Furthermore, in the environment field, the report covers all business sites in Japan and only manufacturing sites overseas. 

Astellas has adopted the International Financial Reporting Standards (IFRS), effective from fiscal 2013. Generally the information in this report is based on IFRS; however, in order to facilitate comparison with information from previous years, some sections are presented following J-GAAP, with an accompanying note. 

To make the report effective as a tool for communicating with our many stakeholders, we have used charts, photographs and other devices to make it easy to understand. 

## notes 

Statements made in this annual report with respect to current plans, estimates, strategies and beliefs and other statements of Astellas that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. Consequently, undue reliance should not be placed on these statements. Astellas cautions the reader that a number of important factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in the Pharmaceutical Affairs Law and other laws and regulations relating to markets of Astellas, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of intellectual property rights of third parties. 

Information about pharmaceutical products (including products currently in development) has been included. This content is not intended to constitute an advertisement or medical advice. 

## INVESTOR RELATIONS 

<img src='content_image/280106.jpg'>

http://www.astellas.com/ en/ir/ 

## CORPORATE SOCIAL RESPONSIBILITy 

<img src='content_image/280107.jpg'>

http://www.astellas.com/ en/csr/ 

Message from the CEO 

S napshot 

Business Strategy 

Review of Operations 

Corporate Governance 

Financial Section 

Note: In the information about pharmaceutical products in this report, market size, market share and product ranking are sourced from IMS Health 

Information Services. ©2013 IMS Health Calculated based on IMS MIDAS 2014Q1 MAT Reprinted with permission 

